BRIEF-Sanofi Says Phase 2B Study Shows duvakitug Efficacious In Ulcerative Colitis, Crohn's Disease

Teva Pharmaceutical Industries Limited Sponsored ADR 0.00% Pre

Teva Pharmaceutical Industries Limited Sponsored ADR

TEVA

31.61

31.75

0.00%

+0.44% Pre

Feb 17 (Reuters) - Sanofi SA SASY.PA:

  • SANOFI AND TEVA’S DUVAKITUG PHASE 2B MAINTENANCE DATA DEMONSTRATED CLINICALLY MEANINGFUL DURABLE EFFICACY IN ULCERATIVE COLITIS AND CROHN’S DISEASE

  • DUVAKITUG WAS WELL TOLERATED AND SAFETY WAS CONSISTENT WITH THE INDUCTION STUDY

  • FINDINGS REINFORCE POTENTIAL OF DUVAKITUG WHICH IS IN ONGOING PHASE 3 PROGRAMS IN UC AND CD

Source text: ID:nGNX1S0ckx

Further company coverage: SASY.PA


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.